OBJECTIVES: There are doubts about the age limit for lung donors and the ideal donor has traditionally been considered to be one younger than 55 years. The objective of this study was to compare the outcomes in lung transplantation between organs from donors older and younger than 60 years.
INTRODUCTION
The use of lung transplantation has been gaining ground in the treatment of terminal-phase pulmonary diseases [1] . The number of transplants performed per year is growing progressively, with improved survival rates [2] . Despite this increase in the number of transplants performed, the growth in demand is still greater, and the discrepancy between the number of patients on the waiting list and the number of available organs remains [3, 4] . The inclusion of expanded-criteria donors has allowed for a significant global increase in the number of lung transplants performed in the last decade, without a negative impact on posttransplant morbidity and mortality rates [5] [6] [7] . One of these criteria is age, as the ideal donor has traditionally been considered to be one younger than 55 years. The mean age of multiorgan donors has increased over the years, and the use of a strict age criterion could imply a major loss in the number of valid organs available for lung transplants. However, there are certain drawbacks to the use of older donors. Studies have shown that the combination of a donor older than 55 years and a prolonged ischaemia time yields higher morbidity rates and lower survivorship [8] . The incidence of bronchiolitis obliterans has also been shown to be lower among recipients of organs from donors younger than 60 years [9] . The use of donors older than 60 years of age is still limited. According to the The International Society for Lung and Heart Transplantation (ISHLT) records, this percentage has remained relatively stable since 2005, at 10% [2] .
In recent years, our hospital has adopted the policy of accepting lungs from donors up to 70 years old. The objective of this study was to evaluate the impact that this change in strategy has had on our programme in terms of the number of transplants performed, and to compare postoperative results and patient survival between recipients of lungs from older and younger donors.
PATIENTS AND METHODS
The lung transplant programme at our hospital was started in 1990, and 670 transplants were performed between this time and the end of 2012. Starting in 2007, we decided to expand our criteria for the acceptance of organ donors due to the scarcity of donated lungs. In terms of age, we started accepting organs from donors up to 70 years old. Our policy has been to assign older donors to older recipients.
Study population
Between January 2007 and December 2011, 253 lung transplants were performed at our hospital. We excluded all paediatric patients younger than 18 years of age (n = 22) and one patient whose donor age was not recorded in the registry from our analysis. This left us with a study sample of 230 transplant patients. Of these, 87 (37.7%) received single-lung and 144 (62.3%) received double-lung transplants. All patients were monitored until the end of 2012, with a mean follow-up period of 27.5 months. We performed a retrospective observational study comparing the group of patients receiving organs from donors 60 years or older (Group A) with the group of patients receiving organs from donors younger than 60 years (Group B). This study was approved by the Vall d'Hebron Hospital clinical research ethics committee.
Lung donor assessment
Donors were initially evaluated by the attending thoracic surgeon based on standard variables, such as age, use of toxic substances, medical history, cause of death, infections, chest X-ray and an arterial blood gas analysis under ventilation with a fraction of inspired oxygen (FiO 2 ) of 1 and a positive end-expiratory pressure of 5 cmH 2 O. The patient was then evaluated by the transplant team through visual inspection and palpation of the lungs, lung recruitment manoeuvres to evaluate pulmonary compliance and a second arterial blood gas evaluation in the operating theatre. Organ recipients were chosen based on blood group compatibility, similarity in lung size based on donor and recipient chest X-rays, height and sex.
Lung retrieval and preservation
The lungs were obtained by en bloc extraction. We administered 10 mg/kg methylprednisolone to all donors, and 3 mg/kg of sodium heparin prior to cannulation of the pulmonary artery. We then administered 0.5 mg of epoprostenol sodium (Flolan®, GlaxoSmithKline, Parma, Italy) directly into the pulmonary artery prior to clamping the thoracic aorta. We continued with antegrade perfusion using a low-potassium dextran electrolyte preservation solution (Perfadex®, Vitrolife, Goteborg, Sweden), making an incision in the left atrium to allow drainage. During perfusion, the lungs were topically cooled using cold saline solution. Finally, the expanded lungs were removed, we performed the backbench organ preparation, and applied retrograde perfusion of the pulmonary veins at the donor hospital, keeping the organs chilled until implantation.
Surgical procedure
Single-lung transplants were performed using an anterior thoracotomy, and sequential double-lung transplants were performed using a bilateral anterior thoracotomy with transverse sternotomy (clamshell approach). We first created the bronchial anastomosis using absorbable monofilament running sutures for the membranous tissue and simple sutures for the cartilaginous tissue. We then created the arterial and left atrial anastomoses. At the start of graft reperfusion, we kept the left atrial end of the anastomosis open to allow for the release of air and intravascular preservation solution. We also administered 500 mg of intravenous methylprednisolone prior to lung reperfusion. Extracorporeal circulation was only used in cases of respiratory or haemodynamic instability that would impede the lung transplant procedure.
Postoperative management
Immunosuppressant treatment was based on corticosteroid, tacrolimus and mycophenolate mofetil. Antibacterial treatment varied based on bacterial cultures for each recipient and for the bronchial aspirate taken from donated lungs. All patients received prophylaxis with co-trimoxazole for Pneumocystis jirovecii, nebulized liposomal amphotericin B for Aspergillus, and valganciclovir for cytomegalovirus (CMV). During the immediate postoperative period, we performed control tests for CMV using polymerase chain reaction of blood samples on a weekly basis, and checked immunosuppression levels every 2 days in addition to cultures of respiratory secretions. One surveillance bronchoscopy with transbronchial biopsy was obtained in all patients. Other bronchoscopy was ordered only by clinical indication.
Variables analysed
Donor-related variables included sex, cause of death, hours of intubation, tobacco use, thoracic trauma, purulent bronchial secretions, chest X-ray results and arterial oxygen partial pressure (PaO 2 ). Recipient variables included age, sex, body mass index (BMI) and underlying pathology. Variables related to the surgical procedure included transplant type (single-lung or double-lung), the use of cardiopulmonary bypass (CPB), ischaemia time and the need for graft volume reduction due to size mismatch.
End points
We reviewed postoperative mortality rates within 30 days, as well as general patient evolution in terms of days on mechanical ventilation, duration of stay in the intensive care unit (ICU) and total hospital stay. We analysed the incidence of severe Grade 3 primary graft dysfunction (PGD) within the first 3 days following the operation [10] . Grade 3 PGD is defined as a PaO 2 /FiO 2 ratio <200 mmHg along with pulmonary infiltrates in a chest X-ray. Episodes of respiratory infection were collected. We evaluated the incidence of biopsy-proven acute cellular rejection during the postoperative period [11] . We assessed CMV infection and chronic lung allograft dysfunction (CLAD). The presence of CLAD was defined as a decrease equal to or greater than 20% of the maximum forced expired volume in 1 s (FEV 1 ) reached during patient evolution following the transplant, with no other justifiable cause [12] . Finally, we analysed the global survival rate.
Statistical analysis
Quantitative variables were summarized as mean ± standard deviation (SD) when the distribution of the data was symmetrical, and as a median and inter-quartile range if the variable showed an asymmetrical distribution. Unpaired Student's t-tests (symmetrical distribution) and Mann-Whitney U-tests (asymmetrically distribution) were used for comparisons. Categorical variables were presented as the absolute number of patients and percentage of the total number of valid values for the variable. We compared these variables between groups using Pearson's χ 2 test. We performed a Kaplan-Meier survival analysis and compared survival using the Mantel-Haenszel test (log-rank test). We considered a P-value of <0.05 to be statistically significant in all cases. We used the Stata 11.2® statistical software for all analyses (StataCorp 2009. Stata Statistical Software 11.0. College Station, TX, USA).
RESULTS
We analysed a total of 230 lung transplants, of which 53 (23%) involved lungs from donors 60 years of age or older (Group A), and 177 (77%) were from donors younger than 60 years (Group B). Since we started accepting donors older than 60 years of age in 2007, the percentage of transplants performed using this type of donor has increased progressively, reaching 32.6% of all donors for transplants in adult patients in 2011 (Fig. 1 ).
Donor characteristics
The mean donor age in Group A was 63.2 ± 2.7 years (range: 60-70 years), and the mean age in Group B was 41.4 ± 13.2 years (range: 13-59 years) ( Table 1 ). More donors in Group B died because of trauma (23.7%). Group A was composed of a significantly lower proportion of smokers and individuals with purulent tracheobronchial secretions compared with Group B. There were no differences between the two groups in the other variables.
Recipient and surgical characteristics
The mean recipient age in Group A was significantly higher than in Group B (Table 2 ). In addition, lungs from 79.2% of donors 60 years or older were transplanted into recipients 50 years or older. The most common pathologies requiring transplantation were chronic obstructive pulmonary disease (COPD) in 37.9% of patients, and pulmonary fibrosis in 35.4%. A greater proportion of patients in Group A had pulmonary fibrosis, and none of the 15 patients in our Tracheobronchial purulent secretions detected in a tracheal aspiration or at bronchoscopy.
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Postoperative outcomes
The global postoperative mortality rate at 30 days was 7.4% (Table 3 ). Three patients from Group A (5.7%) and 14 patients (7.9%) from Group B died within 30 days (P = 0.583). The causes of death within 30 days in Group A were septic shock due to pneumonia in 2 patients, and a haemorrhagic stroke in 1 patient. In Group B, the causes of death within 30 days were septic shock in 5 patients, haemorrhagic shock in 2 patients, cardiogenic shock in 2 patients, dehiscence of the bronchial sutures in 2 patients, PGD in 2 patients and eosinophilic pneumonia in 1 patient. In our univariate analysis of mortality at 30 days, the use of CPB, volume reduction of the lung graft by resection and underlying pathology were all significant risk factors. A donor age equal to or greater than 60 years was not a risk factor for early mortality. The median number of days on mechanical ventilation and stay in the ICU were greater in Group A patients, although this difference did not reach statistical significance (Table 3 ). The total duration of hospital stay following transplantation was greater in Group A patients (39 days) than in Group B patients (32 days) (P = 0.055). If we eliminate patients who died before discharge, these differences were smaller (Table 3 ).
In the global study population, 62.2% of patients exhibited at least one of the three most common types of postoperative complication following lung transplants: PGD, acute rejection and respiratory infections (Table 4) . These complications occurred in 71.7% of Group A patients and 59.3% of Group B patients (P = 0.10). Frequency of respiratory infections was 62.3% in Group A vs 46.9% in Group B (P = 0.05).
Late complications
As regards late complications, there was no difference between the two groups in the frequency of CMV infections ( Table 4) . The Kaplan-Meier analysis revealed a similar incidence of CLAD between the two groups (P = 0.47) (Fig. 2) . The percentage of patients free from CLAD at 1-3 years was 95.5, 74.3 and 69.3% for Group A, and 94.5, 84.8 and 73.3% for Group B, respectively.
Survival
There were no statistically significant differences between Groups A and B in terms of global survival at 3 years. The percentage of survivors at 1-3 years was 77.2, 72.5 and 69.4% for Group A, and 81.6, 75.8 and 68.8% for Group B, respectively (P = 0.28) (Fig. 3) . We did not observe an interaction between donor age and recipient age. After stratifying patients based on recipient age, there were no significant differences between Groups A and B among recipients younger than 50 years ( Fig. 4A ; P = 0.83) or older than 50 years ( Fig. 4B ; P = 0.37). We also did not observe an interaction between total ischaemia time and donor age. In our study, only 13 patients received transplants from donors older than 60 years of age and had a total ischaemia time >6 h, and survival in these transplant recipients was not significantly different from that of other patients. 
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DISCUSSION
The main result of the present study is that the use of donors older than 60 years of age appears as a safe option for lung transplantation, providing global outcomes comparable with those from using younger donors. Perioperative and mid-term outcomes are similar between donor types. In our experience and opposed to Barbara C. Cahill's comment in The Journal of Heart and Lung Transplantation, donors older than 60 years are a useful source of valid lungs and the number of these donors is still increasing over the last years [13] .
The discrepancy between the number of patients waiting for a lung transplant and the number of available donated lungs has led to a progressive expansion of donor selection criteria over the last 20 years. According to Eurotransplant, which compiles information on the lung transplant programmes in Austria, Belgium, Germany and Holland, the increase in the number of patients on the waiting list has been greater than the increase in available lungs. In 2011, a total of 1000 patients were awaiting new lungs, but only 622 transplants were performed [4] . In Spain, we had 478 patients on the waiting list in 2011, of which 230 received transplants, with a 4.6% mortality rate while on the list [3] . These discrepancies have necessitated an increase in the use of expanded-criteria donors, which has yielded positive postoperative and long-term results [6, 14] .
Lung donor age is one factor that has been expanded in recent years, allowing us to acquire a greater number of valid organs for transplantation. The mean age of lung donors has increased in recent years, but the percentage of donors older than 60 years of age used on the international level has remained stable since 2005, at 10% [2] . In our hospital, donors older than 60 years of age comprised 32.6% of all donors for adult lung transplants performed in 2011. Traditionally, the age limit was set at 55 years, and the majority of studies evaluating the effect of donor age on lung transplant success rates established this threshold [15] [16] [17] . Nevertheless, this age limit has been increasing and more recent articles analysed the results of transplants using organs from donors older than 60 years [9, 18] .
One of the dilemmas surrounding the use of older donors is whether to apply the same donor selection criteria to these individuals that we would use with younger donors. Since 2007, we have followed a policy of expanded criteria for lung donors, which are reflected in the frequency of accepting organs from donors who have a history of smoking tobacco, those with prolonged intubation times, sub optimal chest X-ray results or purulent tracheobronchial secretions. However, in light of our data, we can deduce that the process of donor selection has been carried out with greater selectivity among donors older than 60 years of age, with a significantly lower proportion of smokers and donors with purulent respiratory secretions in this group. This tendency is similar to those reported in other studies, in which the characteristics of older donors are more closely aligned with those of the ideal donor [9] . It has been postulated that organs from older donors have a reduced resistance to ischaemia, as evidenced by greater short-term and mid-term mortality rates in recipients of transplants from donors older than 55 years of age and with a total ischaemia time >6-7 h [8, 19] . In our study, we did not observe significant differences between donors older than or younger than 60 years of age in terms of survival of patients receiving transplants under conditions of an ischaemia time >6 h.
One current issue of debate is how to assign lungs from older donors to transplant recipients. Some hospitals reserve these organs for older recipients and situations of great medical urgency, without a negative impact on survival [9] . However, others support the use of organs from donors older than 55 years of age for any type of recipient, regardless of age or severity of the underlying pathology [17] . Our policy has been to assign older donors to older recipients, the 'old for old' concept. Under this policy, almost 80% of organs from donors older than 60 years of age have been used for recipients older than 50 years of age. This has not resulted in a lower global survival rate among recipients of organs from donors older than 60 years.
Postoperative results were similar between the two donor-type groups. Mortality at 30 days was 5.7% in patients receiving lungs from donors older than 60 years and 7.9% for donors younger than 60 years. In contrast, the study by De Perrot et al. [9] observed a tendency towards greater mortality rates at 30 days in patients receiving organs from donors older than 60 years compared with younger donors (17 vs 9%), although this difference was not statistically significant. In a recently published article based on the results of 10 666 lung transplants from the registry of the United Network for Organ Sharing (UNOS) between 2000 and 2009, no significant differences were observed in terms of postoperative mortality when dividing patients into donor age groups of 18-34 years, 35-54 years, 55-64 years and ≥65 years [18] . Mortality rates at 30 days, both in our study and the UNOS database, are similar to each other, and both are lower than those presented by De Perrot et al. This could be due to the fact that this study was carried out between 1994 and 2005, whereas the modern multifactorial improvements in postoperative results for lung transplants have allowed for the use of lungs from older donors while maintaining a low mortality rate at 30 days. Nevertheless, postoperative mechanical ventilation and ICU stay seemed to be longer in the older donor group (13 and 23 days vs 4 and 10 days, respectively). That difference was not observed when we divided patients by recipient age; therefore, donor age could have some independent influence on this result. Doubts arise concerning the resistance of older transplanted lungs to immunological attack and other causes of loss of pulmonary function and CLAD. In the study by the Toronto group, the primary cause of death in patients receiving organs from older donors who survived longer than 90 days was bronchiolitis obliterans, one of the manifestations of CLAD [9] . However, no significant differences in terms of bronchiolitis obliterans incidence rates have been observed in more recent studies [17, 18] . We must keep in mind that, in the study by the Toronto group, the donor age limit was higher, at 77 years, and 16% of donors in the older donor group were older than 70 years. In our study, which included 53 donors older than 60 years and 15 between the ages of 65 and 70 years, we did not observe differences in the incidence of CLAD between older and younger donor groups.
Older age has always been a concern when selecting organ donors, and is considered an important factor affecting transplant results. Results from kidney transplants have indicated reduced graft survival when using organs from donors older than 60 years [20] . In the case of lung transplants, although reports from the ISHLT registries from previous years showed that donor age >55 years was a significant risk factor for mortality at 1 and 5 years, the most recent data no longer indicate a significant effect [2] . Several studies have reported similar survival rates among recipients of organs from donors older than and younger than 55 years [15] [16] [17] . In the study by De Perrot et al. involving 60 donors older than 60 years, survival rates at 5 and 10 years were lower among recipients of organs from older donors than from younger donors [9] . We did not observe a significant difference in survival at 3 years between patients receiving transplants from donors older than or younger than 60 years. The upper age limit for accepting lung donations is a controversial issue, and we need more experience and data to be able to reach solid conclusions.
Our study involved certain limitations. First, the retrospective design implies several inherent drawbacks. Another limitation when comparing between donor groups was the fact that the selection of donors older than 60 years was more stringent in terms of other criteria, and so we could be comparing different profiles of lung donors. The small sample size limited the statistical power, and some differences, such as the hospital stay, could have been statistically significant. In addition, the follow-up period, although sufficient to evaluate postoperative outcomes and survival at 3 years, did not allow us to assess longer-term results because there are not enough patients at risk currently. Finally, we did not have any donors older than 70 years, thus preventing the possibility of an analysis of that group.
In summary, our results support the idea that lungs from donors aged 60-70 years can be used safely for transplants, presenting comparable results to those of younger donors in terms of postoperative mortality and mid-term survival. In our experience, we did not observe a greater incidence of chronic dysfunction in the lungs from donors older than 60 years. The combination of older donors and older recipients also did not have a negative effect, implying that the assignment of older donors to older recipients is a feasible practice.
